查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1584079

鉅细胞病毒 (CMV) 测试市场，按样本类型、按药物类型、按测试类型、按最终用户、按应用、按国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Cytomegalovirus (CMV) Tests Market, By Sample Type, By Drug Type, By Test Type, By End User, By Application, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 316 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023 年鉅细胞病毒 (CMV) 测试市场规模为 4,990 万美元，2024 年至 2032 年复合年增长率为 1.01%。

鉅细胞病毒（CMV）测试市场-市场动态

CMV 感染的发生率不断上升，人们对病毒的认识不断提高，以及开发新的、更有效的治疗方案来推动市场需求

大多数医生建议对疑似胎儿畸形或反覆流产的患者进行鉅细胞病毒（CMV）检测，这有助于市场成长。 CMV 检测对于检测这种病毒至关重要，这种病毒可能导致免疫功能低下的个体和婴儿严重疾病。作为分布广泛的病原体，鉅细胞病毒是全球先天性感染的主要原因。它是一种人类疱疹病毒，可透过与受感染体液的密切接触以及经胎盘转移、输血或器官移植进行传播。 CMV 治疗市场受到多种因素的推动，包括 CMV 感染盛行率上升、人们对该病毒的认识提高以及新的更有效治疗方案的开发。常见的 CMV 治疗包括抗病毒药物、免疫球蛋白治疗和干细胞移植。慢性病发病率不断上升、对个人化医疗的需求以及发展中国家治疗方法的不断增加进一步推动了这个市场。根据国家医学图书馆 2023 年 8 月发表的一篇文章，大约 59% 的六岁以上个体曾感染过 CMV，且血清阳性率随着年龄的增长而增加。 CMV 感染可表现为原发性感染、再感染或再激活，透过各种传播方式发生，如血液製品、母乳哺育、密切接触环境、围产期传播和性接触。再激活在免疫功能低下的患者中尤其令人担忧，因为它与发病率和死亡率增加有关。对于免疫力完整的个体来说，CMV 很少导致死亡；然而，对于接受化疗或服用皮质类固醇的免疫功能低下的患者来说，它可能会导致严重的健康问题。骨髓移植后，与 CMV 相关的死亡率在 10% 至 75% 之间变化，进一步推动了 CMV 治疗市场的发展。此外，CMV 感染工业化国家约 60% 至 70% 的成年人，以及新兴国家近 100% 的成年人。在疱疹病毒中，CMV 拥有数量最多的专门用于逃避先天性和适应性免疫反应的基因。这种病毒对 T 细胞抗原监视带来负担，并导致免疫功能障碍。此外，先天性鉅细胞病毒是导致学习障碍、失聪和智力障碍的主要原因，使其成为鉅细胞病毒治疗市场的重要驱动力。

鉅细胞病毒 (CMV) 测试市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032）每年将以 1.01% 左右的复合年增长率成长

根据测试类型细分，核酸扩增测试 (NAAT) 预计将在 2023 年显示最大的市场份额

根据药物类型细分，缬更昔洛韦是2023年的主导类型

按地区划分，北美是 2023 年的主要收入来源

鉅细胞病毒 (CMV) 测试市场区隔分析：

全球鉅细胞病毒 (CMV) 测试市场根据样本类型、药物类型、测试类型、最终用户、应用和区域进行细分。

根据检验类型，市场分为三类：酵素免疫测定/酵素连结免疫吸附测定（EIA/ELISA）检验、核酸扩增检验（NAAT）和其他CMV检验。其中，CMV 核酸扩增检测 (NAAT) 领域在 2023 年占据市场份额，这主要是由于其在检测病毒 DNA 方面的高灵敏度和特异性。 NAAT 在临床环境中特别有利，因为它们能够早期、准确地诊断 CMV 感染，特别是对于免疫功能低下的患者，及时介入对于预防严重併发症至关重要。

依药物类型，市场分为五类：缬更昔洛韦、更昔洛韦、西多福韦、膦甲酸等。在鉅细胞病毒(CMV) 检测市场中，缬更昔洛韦脱颖而出，成为领先的药物类型，这主要是由于其口服生物利用度以及预防和治疗CMV 感染（尤其是免疫功能低下患者）的有效性。与更昔洛韦等静脉注射替代品相比，它的给药简便性提高了其在临床环境中的受欢迎程度。儘管更昔洛韦仍然很重要，特别是在急性情况下，并且西多福韦和膦甲酸等其他药物也用于治疗抗药性病例，但缬更昔洛韦经过验证的疗效和用户友好的管理使其成为医疗保健专业人员的首选。这一趋势凸显了在管理鉅细胞病毒感染方面更广泛地转向以患者为中心的治疗解决方案。

鉅细胞病毒 (CMV) 测试市场 - 地理洞察

北美是鉅细胞病毒 (CMV) 测试市场的主导地区，这主要是由于其先进的医疗基础设施、抗生素抗药性感染的高盛行率以及在研发方面的大量投资。该地区的医院是这些抗生素（尤其是万古霉素）的主要消费者，用于治疗 MRSA 等严重的革兰氏阳性感染。此外，支持性监管框架和对感染控制的高度重视导致对鉅细胞病毒（CMV）检测的需求不断增长。该地区主要製药公司的存在和正在进行的临床试验进一步增强了其市场领导地位。

鉅细胞病毒 (CMV) 测试市场竞争格局：

CMV 测试市场的公司采取各种策略来加强其市场影响力并促进创新。主要重点是投资于研发，以提高测试方法的敏感度和特异性，同时创建快速诊断解决方案。与医疗保健提供者和实验室的合作有助于简化测试流程并收集对临床需求的见解。针对医疗保健专业人员和机构的行销活动强调了早期发现和管理鉅细胞病毒相关疾病的重要性。此外，公司还开展教育活动，以提高人们对 CMV 风险的认识，从而扩大其检测产品和服务的市场。

最新进展：

2022 年 9 月，ProBioGen 与希望之城达成协议，生产用于临床试验和商业分销的 CMV 疫苗，加速了疫苗的开发和生产，并有望挽救无数生命。

目录

第 1 章：鉅细胞病毒 (CMV) 测试市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 鉅细胞病毒 (CMV) 以样本类型测试市场片段
    • 鉅细胞病毒 (CMV) 依药物类型测试市场片段
    • 按测试类型分類的鉅细胞病毒 (CMV) 测试市场片段
    • 最终用户的鉅细胞病毒 (CMV) 测试市场片段
    • 鉅细胞病毒 (CMV) 按应用测试市场片段
    • 鉅细胞病毒 (CMV) 测试市场片段（按国家/地区）
    • 鉅细胞病毒 (CMV) 测试市场片段（按地区）
  • 竞争洞察

第 3 章：鉅细胞病毒 (CMV) 测试主要市场趋势

  • 鉅细胞病毒（CMV）测试市场驱动因素
    • 市场驱动因素的影响分析
  • 鉅细胞病毒（CMV）测试市场限制
    • 市场限制影响分析
  • 鉅细胞病毒 (CMV) 测试市场机会
  • 鉅细胞病毒（CMV）测试市场未来趋势

第 4 章：鉅细胞病毒 (CMV) 测试产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：鉅细胞病毒 (CMV) 测试市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：鉅细胞病毒 (CMV) 测试市场格局

  • 鉅细胞病毒 (CMV) 测试市场占有率分析，2023 年
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：鉅细胞病毒 (CMV) 测试市场 - 依样本类型

  • 概述
    • 按样本类型分類的细分市场占有率分析
    • 尿
    • 血

第 8 章：鉅细胞病毒 (CMV) 测试市场 - 按药物类型

  • 概述
    • 按药物类型分類的细分市场份额分析
    • 缬更昔洛韦
    • 更昔洛韦
    • 西多福韦
    • 膦甲酸
    • 其他的

第 9 章：鉅细胞病毒 (CMV) 测试市场 - 按测试类型

  • 概述
    • 按测试类型分類的细分市场份额分析
    • 酵素免疫分析/酵素连结免疫吸附分析（EIA/ELISA）测试
    • 核酸扩增检验 (NAAT)
    • 其他 CMV 测试

第 10 章：鉅细胞病毒 (CMV) 测试市场 - 由最终用户

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 医院
    • 诊断中心
    • 诊所
    • 其他的

第 11 章：鉅细胞病毒 (CMV) 测试市场 - 按应用

  • 概述
    • 按应用分類的细分市场占有率分析
    • 视网膜炎
    • 肺炎
    • 胃肠道溃疡
    • 脑炎
    • 干细胞移植
    • 器官移植
    • 其他（口腔溃疡、咽炎等）

第 12 章：鉅细胞病毒 (CMV) 测试市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 鉅细胞病毒 (CMV) 对北美主要製造商进行测试
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按样本类型）
    • 北美市场规模和预测（按药物类型）
    • 北美市场规模和预测（按测试类型）
    • 北美市场规模和预测（按最终用户）
    • 北美市场规模和预测（按应用）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 鉅细胞病毒 (CMV) 对欧洲主要製造商进行测试
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按样本类型）
    • 欧洲市场规模和预测（按药物类型）
    • 欧洲市场规模和预测（按测试类型）
    • 欧洲市场规模和预测（按最终用户）
    • 欧洲市场规模和预测（按应用）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 鉅细胞病毒 (CMV) 对亚太地区主要製造商进行测试
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（依样本类型）
    • 亚太地区市场规模和预测（按药物类型）
    • 按测试类型分類的亚太市场规模和预测
    • 亚太地区市场规模和预测（按最终用户）
    • 亚太地区市场规模与预测（按应用）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 鉅细胞病毒 (CMV) 对拉丁美洲的主要製造商进行测试
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模和预测（按样本类型）
    • 拉丁美洲市场规模与预测（按药物类型）
    • 拉丁美洲市场规模和预测（按测试类型）
    • 拉丁美洲市场规模和预测（按最终用户）
    • 拉丁美洲市场规模与预测（按应用）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 鉅细胞病毒 (CMV) 对中东和非洲的主要製造商进行测试
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按样本类型）
    • 中东和非洲市场规模及预测（按药物类型）
    • 中东和非洲市场规模及预测（按测试类型）
    • 中东和非洲市场规模及预测（按最终用户）
    • 中东和非洲市场规模及预测（按应用）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 13 章：主要供应商分析 - 鉅细胞病毒 (CMV) 测试产业

  • 竞争仪表板
  • 公司简介
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Novartis AG
    • Mylan NV
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • F. Hoffmann-La Roche Ltd.
    • Zydus Cadila
    • Lupin
    • Cipla Inc.
    • Aurobindo Pharma
    • Glenmark Pharmaceuticals Limited
    • Endo International plc
    • AstraZeneca
    • Johnson & Johnson Private Limited
    • Bio-Rad Laboratories, Inc.
    • BD
    • Others

第 14 章：360 度分析师视角

第 15 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4075

REPORT HIGHLIGHT

Cytomegalovirus (CMV) Tests Market size was valued at USD 49.90 Million in 2023, expanding at a CAGR of 1.01% from 2024 to 2032.

Cytomegalovirus (CMV) tests are diagnostic tools designed to identify the presence of CMV, a widespread virus that can lead to serious health complications, particularly in immunocompromised individuals and newborns. These tests often utilize laboratory techniques, including polymerase chain reaction (PCR) for detecting viral DNA, as well as serological methods to identify the antibodies against CMV. Early detection is vital for managing potential complications, such as congenital CMV infection in infants or opportunistic infections in transplant recipients. Accurate testing enables timely intervention and monitoring, making CMV testing a critical aspect of healthcare for at-risk populations.

Cytomegalovirus (CMV) Tests Market- Market Dynamics

Increasing incidence prevalence of the CMV infections, increased awareness about virus, and the development of new and more effective treatment options to propel market demand

Most physicians recommend cytomegalovirus (CMV) tests for patients with suspected fetal abnormalities or recurrent miscarriages, contributing to market growth. CMV tests are essential for detecting this virus, which can lead to serious illnesses in immunocompromised individuals and infants. As a widely distributed pathogen, CMV is the leading cause of congenital infections globally. It is a human herpesvirus that can be transmitted through intimate contact with infected bodily fluids, as well as via transplacental transfer, blood transfusions, or organ transplants. The CMV treatment market is propelled by several factors, including the rising prevalence of CMV infections, increased awareness about the virus, and the development of new and more effective treatment options. Common CMV treatments include antiviral medications, immunoglobulin therapy, and stem cell transplantation. This market is further driven by the growing incidence of chronic diseases, the demand for personalized medicine, and the increasing availability of treatments in developing countries. According to an August 2023 article published by the National Library of Medicine, approximately 59% of individuals over six years old have encountered CMV, with seroprevalence increasing with age. CMV infections can manifest as primary infections, reinfections, or reactivations, occurring through various transmission modes such as blood products, breastfeeding, close-contact settings, perinatal transmission, and sexual contact. Reactivation is particularly concerning in immunocompromised patients, as it is associated with increased morbidity and mortality. For individuals with intact immunity, CMV rarely results in death; however, in immunocompromised patients undergoing chemotherapy or taking corticosteroids, it can lead to significant health issues. Following bone marrow transplants, reported mortality rates related to CMV vary between 10% and 75%, further boosting the CMV treatment market. Moreover, CMV infects approximately 60% to 70% of adults in industrialized countries and nearly 100% in emerging countries. Among herpesviruses, CMV has the largest number of genes specifically designed to evade both innate and adaptive immune responses. This virus poses a burden on T-cell antigenic surveillance and contributes to immune dysfunction. Additionally, congenital CMV is a primary infectious cause of learning disabilities, deafness, and intellectual disabilities, making it a significant driver for the CMV treatment market.

Cytomegalovirus (CMV) Tests Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 1.01% over the forecast period (2024-2032)

Based on Test Type segmentation, nucleic acid amplification tests (NAATs) was predicted to show maximum market share in the year 2023

Based on Drug Type segmentation, Valganciclovir was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Cytomegalovirus (CMV) Tests Market- Segmentation Analysis:

The Global Cytomegalovirus (CMV) Tests Market is segmented on the basis of Sample Type, Drug Type, Test Type, End User, Application, and Region.

The market is divided into three categories based on Test Type: enzyme immunoassay/enzyme-linked immunosorbent assay (EIA/ELISA) tests, nucleic acid amplification tests (NAATs), and other CMV tests. Among these, the CMV nucleic acid amplification tests (NAATs) segment led the market share in 2023, primarily due to their high sensitivity and specificity in detecting viral DNA. NAATs are particularly advantageous in clinical settings because they enable early and accurate diagnosis of CMV infections, especially in immunocompromised patients, where timely intervention is critical to preventing severe complications.

The market is divided into five categories based on Drug Type: Valganciclovir, Ganciclovir, Cidofovir, Foscarnet and Others. In the cytomegalovirus (CMV) tests market, Valganciclovir stands out as the leading drug type, largely due to its oral bioavailability and effectiveness in preventing and treating CMV infections, especially in immunocompromised patients. Its ease of administration compared to intravenous alternatives like Ganciclovir enhances its popularity in clinical settings. Although Ganciclovir remains significant, particularly in acute situations, and other medications such as Cidofovir and Foscarnet are employed for resistant cases, Valganciclovir's proven efficacy and user-friendly administration make it the preferred option among healthcare professionals. This trend underscores a wider movement toward more patient-centric treatment solutions in managing CMV infections.

Cytomegalovirus (CMV) Tests Market- Geographical Insights

North America is the dominating region in the Cytomegalovirus (CMV) Tests market, primarily due to its advanced healthcare infrastructure, high prevalence of antibiotic-resistant infections, and significant investments in research and development. The region's hospitals are major consumers of these antibiotics, particularly Vancomycin, to manage serious Gram-positive infections like MRSA. Furthermore, supportive regulatory frameworks and a strong emphasis on infection control contribute to the growing demand for Cytomegalovirus (CMV) Tests. The presence of key pharmaceutical companies and ongoing clinical trials in this region further enhance its market leadership.

Cytomegalovirus (CMV) Tests Market- Competitive Landscape:

Companies in the CMV tests market adopt various strategies to strengthen their market presence and foster innovation. A primary focus is on investing in research and development to enhance the sensitivity and specificity of testing methods while creating rapid diagnostic solutions. Collaborations with healthcare providers and laboratories help streamline testing processes and gather insights into clinical needs. Marketing initiatives highlight the significance of early detection and management of CMV-related conditions, targeting healthcare professionals and institutions. Additionally, companies engage in educational campaigns to raise awareness about CMV risks, thereby expanding the market for their testing products and services.

Recent Developments:

In September 2022, ProBioGen entered into an agreement with the City of Hope to manufacture the CMV vaccine for clinical trials and commercial distribution, accelerating the development and production of the vaccine that could potentially save numerous lives.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CYTOMEGALOVIRUS (CMV) TESTS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • F. Hoffmann-La Roche Ltd.
  • Zydus Cadila
  • Lupin
  • Cipla Inc.
  • Aurobindo Pharma
  • Glenmark Pharmaceuticals Limited
  • Endo International plc
  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Bio-Rad Laboratories, Inc.
  • BD
  • Others

GLOBAL CYTOMEGALOVIRUS (CMV) TESTS MARKET, BY SAMPLE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Urine
  • Blood

GLOBAL CYTOMEGALOVIRUS (CMV) TESTS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Valganciclovir
  • Ganciclovir
  • Cidofovir
  • Foscarnet
  • Others

GLOBAL CYTOMEGALOVIRUS (CMV) TESTS MARKET, BY TEST TYPE- MARKET ANALYSIS, 2019 - 2032

  • Enzyme immunoassay/enzyme-linked immunosorbent assay (EIA/ELISA) tests
  • Nucleic acid amplification tests (NAATs)
  • Other CMV tests

GLOBAL CYTOMEGALOVIRUS (CMV) TESTS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Diagnostic Centres
  • Clinics
  • Others

GLOBAL CYTOMEGALOVIRUS (CMV) TESTS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Retinitis
  • Pneumonia
  • Gastrointestinal ulcers
  • Encephalitis
  • Stem cell transplantation
  • Organ transplantation
  • Others (Mouth Ulcers, Pharyngitis, etc.)

GLOBAL CYTOMEGALOVIRUS (CMV) TESTS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Cytomegalovirus (CMV) Tests Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Cytomegalovirus (CMV) Tests Market Snippet by Sample Type
    • 2.1.2. Cytomegalovirus (CMV) Tests Market Snippet by Drug Type
    • 2.1.3. Cytomegalovirus (CMV) Tests Market Snippet by Test Type
    • 2.1.4. Cytomegalovirus (CMV) Tests Market Snippet by End User
    • 2.1.5. Cytomegalovirus (CMV) Tests Market Snippet by Application
    • 2.1.6. Cytomegalovirus (CMV) Tests Market Snippet by Country
    • 2.1.7. Cytomegalovirus (CMV) Tests Market Snippet by Region
  • 2.2. Competitive Insights

3. Cytomegalovirus (CMV) Tests Key Market Trends

  • 3.1. Cytomegalovirus (CMV) Tests Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Cytomegalovirus (CMV) Tests Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Cytomegalovirus (CMV) Tests Market Opportunities
  • 3.4. Cytomegalovirus (CMV) Tests Market Future Trends

4. Cytomegalovirus (CMV) Tests Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Cytomegalovirus (CMV) Tests Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Cytomegalovirus (CMV) Tests Market Landscape

  • 6.1. Cytomegalovirus (CMV) Tests Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Cytomegalovirus (CMV) Tests Market - By Sample Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Sample Type, 2023 & 2032 (%)
    • 7.1.2. Urine
    • 7.1.3. Blood

8. Cytomegalovirus (CMV) Tests Market - By Drug Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
    • 8.1.2. Valganciclovir
    • 8.1.3. Ganciclovir
    • 8.1.4. Cidofovir
    • 8.1.5. Foscarnet
    • 8.1.6. Others

9. Cytomegalovirus (CMV) Tests Market - By Test Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Test Type, 2023 & 2032 (%)
    • 9.1.2. Enzyme immunoassay/enzyme-linked immunosorbent assay (EIA/ELISA) tests
    • 9.1.3. Nucleic acid amplification tests (NAATs)
    • 9.1.4. Other CMV tests

10. Cytomegalovirus (CMV) Tests Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Diagnostic Centres
    • 10.1.4. Clinics
    • 10.1.5. Others

11. Cytomegalovirus (CMV) Tests Market - By Application

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Application, 2023 & 2032 (%)
    • 11.1.2. Retinitis
    • 11.1.3. Pneumonia
    • 11.1.4. Gastrointestinal ulcers
    • 11.1.5. Encephalitis
    • 11.1.6. Stem cell transplantation
    • 11.1.7. Organ transplantation
    • 11.1.8. Others (Mouth Ulcers, Pharyngitis, etc.)

12. Cytomegalovirus (CMV) Tests Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Cytomegalovirus (CMV) Tests Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Cytomegalovirus (CMV) Tests Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.10. Italy
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. Italy Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.10.4. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.10.5. Italy Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.10.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.10.7. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.11. United Kingdom
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. United Kingdom Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.11.4. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.11.5. United Kingdom Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.11.6. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.11.7. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.12. France
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. France Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.12.4. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.12.5. France Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.12.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.12.7. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.13. Russia
      • 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.2. Russia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.13.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Russia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.14. Netherlands
      • 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.2. Netherlands Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.14.3. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. Netherlands Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.14.5. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.14.6. Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.2. Sweden Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.16. Poland
      • 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.2. Poland Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.16.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Poland Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.17. Rest of Europe
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Rest of the Europe Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Rest of the Europe Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Cytomegalovirus (CMV) Tests Key Manufacturers in Asia Pacific
    • 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. Asia Pacific Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 12.4.5. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.4.6. Asia Pacific Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 12.4.7. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.8. Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.9. India
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. India Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.9.4. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.9.5. India Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.9.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.9.7. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.10. China
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. China Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.10.4. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.10.5. China Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.10.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.10.7. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.14. Thailand
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Thailand Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Thailand Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.15. Indonesia
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Indonesia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Indonesia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.5. Latin America
    • 12.5.1. Overview
    • 12.5.2. Cytomegalovirus (CMV) Tests Key Manufacturers in Latin America
    • 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. Latin America Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 12.5.5. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.5.6. Latin America Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 12.5.7. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.8. Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Cytomegalovirus (CMV) Tests Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Cytomegalovirus (CMV) Tests Industry

  • 13.1. Competitive Dashboard
  • 13.2. Company Profiles
    • 13.2.1. Pfizer Inc.
    • 13.2.2. GlaxoSmithKline plc
    • 13.2.3. Novartis AG
    • 13.2.4. Mylan N.V.
    • 13.2.5. Teva Pharmaceutical Industries Ltd.
    • 13.2.6. Sanofi
    • 13.2.7. F. Hoffmann-La Roche Ltd.
    • 13.2.8. Zydus Cadila
    • 13.2.9. Lupin
    • 13.2.10. Cipla Inc.
    • 13.2.11. Aurobindo Pharma
    • 13.2.12. Glenmark Pharmaceuticals Limited
    • 13.2.13. Endo International plc
    • 13.2.14. AstraZeneca
    • 13.2.15. Johnson & Johnson Private Limited
    • 13.2.16. Bio-Rad Laboratories, Inc.
    • 13.2.17. BD
    • 13.2.18. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us